HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) A correction has been published Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tralins, K. S. Articles by Spence, A. M. Search for Related Content PubMed PubMed Citation Articles by Tralins, K. S. Articles by Spence, A. M.

Volumetric Analysis of ¹⁸F-FDG PET in Glioblastoma Multiforme: Prognostic Information and Possible Role in Definition of Target Volumes in Radiation Dose Escalation

¹ Department of Radiation Oncology, University of Washington Medical Center, Seattle, Washington
² Department of Nuclear Medicine, University of Washington Medical Center, Seattle, Washington
³ Department of Neurosurgery, University of Washington Medical Center, Seattle, Washington
⁴ Department of Neuro-Oncology, University of Washington Medical Center, Seattle, Washington

The use of ¹⁸F-FDG PET for brain tumors has been shown to be accurate in identifying areas of active disease. Radiation dose escalation in the treatment of glioblastoma multiforme (GBM) may lead to improved disease control. On the basis of these premises, we initiated a pilot study to investigate the use of ¹⁸F-FDG PET for the guidance of radiation dose escalation in the treatment of GBM. Methods: Patients were considered eligible to participate in the study if they had a diagnosis of GBM, were at least 18 y old, and had a score of at least 60 on the Karnofsky Scale. Patients were treated with standard conformal fractionated radiotherapy (1.8 Gy per fraction, to 59.4 Gy), with volumes defined by MRI. At a dose of 45–50.4 Gy, patients underwent ¹⁸F-FDG PET for boost target delineation. Final noncoplanar fields (3–4) were designed to treat the volume of abnormal ¹⁸F-FDG uptake plus a 0.5-cm margin for an additional 20 Gy (2 Gy per fraction), to a total dose of 79.4 Gy. If no abnormal ¹⁸F-FDG uptake was observed, treatment was stopped after the conventional course of 59.4 Gy. Age, Karnofsky score, MRI-based volumes, and ¹⁸F-FDG PET volume were analyzed as prognostic variables for time to tumor progression (TTP) and overall survival. ¹⁸F-FDG PET volumes and MRI-based volumes were compared to assess concordance. Results: For the 27 patients who could be evaluated, median actuarial TTP was 43 wk, and median actuarial survival was 70 wk. On univariate analysis, ¹⁸F-FDG PET, T1-weighted MRI gadolinium enhancement (excluding nonenhancing resection cavity), and T2-weighted MRI volumes were significantly predictive of TTP. On multivariate analysis, only ¹⁸F-FDG PET volume retained significance for predicting TTP. Similar results were obtained on analysis of these variables as prognostic factors for survival. When ¹⁸F-FDG PET-based volumes were compared with MRI-based volumes, a difference of at least 25% was detected in all patients, with all but 2 having smaller ¹⁸F-FDG PET volumes. Of patients in whom ¹⁸F-FDG uptake was initially present but treatment subsequently failed, 83% demonstrated the first tumor progression within the region of abnormal ¹⁸F-FDG uptake. Conclusion: In comparison with MRI, ¹⁸F-FDG PET defined unique volumes for radiation dose escalation in the treatment of GBM. ¹⁸F-FDG PET volumes were predictive of survival and time to tumor progression in the treatment of patients with GBM.

Key Words: glioblastoma multiforme • PET • radiation dose escalation

This article has been cited by other articles:

				J. Marik, A. Ogasawara, B. Martin-McNulty, J. Ross, J. E. Flores, H. S. Gill, J. N. Tinianow, A. N. Vanderbilt, M. Nishimura, F. Peale, et al. PET of Glial Metabolism Using 2-18F-Fluoroacetate J. Nucl. Med., June 1, 2009; 50(6): 982 - 990. [Abstract] [Full Text] [PDF]

				K. J. Stelzer, J. G. Douglas, D. A. Mankoff, D. L. Silbergeld, K. A. Krohn, G. E. Laramore, and A. M. Spence Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme Neuro-oncol, February 1, 2008; 10(1): 88 - 92. [Abstract] [Full Text] [PDF]

				R. J. Francis, M. J. Byrne, A. A. van der Schaaf, J. A. Boucek, A. K. Nowak, M. Phillips, R. Price, A. P. Patrikeos, A. W. Musk, and M. J. Millward Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans J. Nucl. Med., September 1, 2007; 48(9): 1449 - 1458. [Abstract] [Full Text] [PDF]

				W. Chen Clinical Applications of PET in Brain Tumors J. Nucl. Med., September 1, 2007; 48(9): 1468 - 1481. [Abstract] [Full Text] [PDF]

				S. A. Kwee, J. P. Ko, C. S. Jiang, M. R. Watters, and M. N. Coel Solitary Brain Lesions Enhancing at MR Imaging: Evaluation with Fluorine 18 Fluorocholine PET Radiology, August 1, 2007; 244(2): 557 - 565. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469. [Abstract] [Full Text] [PDF]

				M. Levivier, N. Massager, D. Wikler, J. Lorenzoni, S. Ruiz, D. Devriendt, P. David, F. Desmedt, S. Simon, P. Van Houtte, et al. Use of Stereotactic PET Images in Dosimetry Planning of Radiosurgery for Brain Tumors: Clinical Experience and Proposed Classification J. Nucl. Med., July 1, 2004; 45(7): 1146 - 1154. [Abstract] [Full Text] [PDF]